- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Arrowhead Research Corporation (ARWR 1.02, 0.00, 0.00%) today announced that Dr. Christopher Anzalone, Chief Executive Officer, will be presenting at the Oppenheimer 21st Annual Healthcare Conference at 10:50 a.m. ET on Tuesday, November 2, 2010, at the Waldorf-Astoria Hotel in New York City, NY. Dr. Anzalone plans to provide a corporate summary and update on the Company's progress.
Dr. Anzalone will also host one-on-one meetings with members of the professional community in New York on November 3-4, 2010. Professional investors can schedule a meeting with Dr. Anzalone by contacting Brandi Floberg at 212-481-2050 or Those investors attending the conference are encouraged to sign up to meet with Dr. Anzalone at the conference through their Oppenheimer sales representative.
Over more than 20 years, the Oppenheimer Healthcare Conference has become a highly valuable investor conference in this sector. The conference will include a core group of public and private companies who are leaders and pioneers in the pharmaceutical, biotechnology, medical device, healthcare facility, health technology and distribution, provider and service industries.
About Arrowhead Research Corporation
Arrowhead Research Corporation (ARWR 1.02, 0.00, 0.00%) is a nanotechnology company commercializing new technologies in the areas of life sciences and electronics. Arrowhead is seeking to build value for shareholders through the progress of its subsidiaries and investments. Currently, Arrowhead is focused primarily on its two majority owned subsidiaries: Unidym, a leader in carbon nanotube technology for electronic applications, and Calando, at the forefront of clinical application of RNAi delivery technology. Arrowhead also has minority investments in two privately held nanobiotech companies.
For more information, please click here
The Piacente Group
Brandi Floberg, 212-481-2050
Copyright © Arrowhead Research CorporationIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Arrowhead to Webcast Fiscal 2015 Year End Results December 7th, 2015
Haydale Announce Year End Results November 3rd, 2015
Call for NanoArt and Art-Science-Technology Papers June 9th, 2016
Novel gene therapy shows potential for lung repair in asthma May 18th, 2016